SEC Form SC 13G filed by XOMA Corporation

2/9/22 10:04:18 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $XOMA alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No. 0 XOMA CORP COMMON STOCK Cusip #98419J206 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #98419J206 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 887,522 Item 8: 0 Item 9: 887,522 Item 11: 7.846% Item 12: HC Cusip #98419J206 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 887,522 Item 8: 0 Item 9: 887,522 Item 11: 7.846% Item 12: IN Item 1(a). Name of Issuer: XOMA CORP Item 1(b). Address of Issuer's Principal Executive Offices: 2200 POWELL STREET, SUITE 310 EMERYVILLE, CA 94608 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 98419J206 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 887,522 (b) Percent of Class: 7.846% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: 0 (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 887,522 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of XOMA CORP. No one other person's interest in the COMMON STOCK of XOMA CORP is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2022 Date /s/ Kevin M. Meagher Signature Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC * IA * Entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on this Schedule 13G. Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act ("Fidelity Funds") advised by Fidelity Management & Research Company LLC ("FMR Co. LLC"), a wholly owned subsidiary of FMR LLC, which power resides with the Fidelity Funds' Boards of Trustees. FMR Co. LLC carries out the voting of the shares under written guidelines established by the Fidelity Funds' Boards of Trustees. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on February 8, 2022, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of XOMA CORP at December 31, 2021. FMR LLC By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 28, 2018, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Kevin M. Meagher Kevin M. Meagher Duly authorized under Power of Attorney effective as of September 30, 2018, by and on behalf of Abigail P. Johnson* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on October 9, 2018, accession number: 0000315066-18-002414.

Get the next $XOMA alert in real time by email

Date

Price Target

Rating

Analyst

4/29/2024

$40.00

Outperform

Leerink Partners

10/8/2021

$56.00 → $69.00

Buy

HC Wainwright & Co.

9/9/2021

$60.00 → $56.00

Buy

Aegis Capital

9/7/2021

$22.00

Outperform → Neutral

Wedbush

9/7/2021

$22.00

Neutral → Underperform

Wedbush

6/29/2021

$60.00

Buy

Aegis Capital

SEC Form SC 13G filed by XOMA Corporation

Chat with this insight

Recent Analyst Ratings for $XOMA

$XOMA Leadership Updates

Live Leadership Updates

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

Actym Therapeutics Appoints Thomas Smart as CEO

XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

$XOMA Press Releases

Fastest customizable press release news feed in the world

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Twist Bioscience Enters into Royalty Purchase Agreement with XOMA Royalty for $15 Million in Cash

$XOMA SEC Filings

SEC Form 8-K filed by XOMA Royalty Corporation

SEC Form 10-Q filed by XOMA Royalty Corporation

SEC Form 8-K filed by XOMA Royalty Corporation

$XOMA Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Sitko Bradley bought $24,848 worth of shares (1,750 units at $14.20), increasing direct ownership by 45% to 5,600 units (SEC Form 4)

Hughes Owen bought $13,830 worth of shares (1,000 units at $13.83), increasing direct ownership by 40% to 3,500 units (SEC Form 4)

Hughes Owen bought $36,075 worth of shares (2,500 units at $14.43) (SEC Form 4)

$XOMA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Leerink Partners initiated coverage on XOMA with a new price target

HC Wainwright & Co. reiterated coverage on XOMA with a new price target

Aegis Capital reiterated coverage on XOMA with a new price target

$XOMA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SVP, Finance & CFO Burns Thomas M. converted options into 17,773 shares and sold $292,664 worth of shares (9,775 units at $29.94), increasing direct ownership by 122% to 14,553 units (SEC Form 4)

Chief Executive Officer Hughes Owen converted options into 53,360 shares and sold $655,336 worth of shares (21,881 units at $29.95), increasing direct ownership by 899% to 34,979 units (SEC Form 4)

Wyszomierski Jack L was granted 6,070 shares, increasing direct ownership by 94% to 12,533 units (SEC Form 4)

$XOMA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

$XOMA Financials

Live finance-specific insights

$XOMA Market Insights

Live Market Insights

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

Zevra's MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

XOMA Royalty Declares Quarterly Preferred Stock Dividends

FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base

Demystifying XOMA: Insights From 5 Analyst Reviews

HC Wainwright & Co. Reiterates Buy on XOMA, Maintains $74 Price Target

Recent Analyst Ratings for
$XOMA

$XOMA
Leadership Updates

$XOMA
Press Releases

$XOMA
SEC Filings

$XOMA
Insider Purchases

$XOMA
Analyst Ratings

$XOMA
Insider Trading

$XOMA
Large Ownership Changes

$XOMA
Financials

$XOMA
Market Insights